Aeglea BioTherapeutics to Present at BIO Digital 2020
Rhea-AI Summary
Aeglea BioTherapeutics (NASDAQ: AGLE) will present a corporate overview at BIO Digital from June 8-12, 2020. The presentation will be led by President and CEO Anthony G. Quinn, M.B. Ch.B., Ph.D. It can be accessed on-demand by registered participants and will also be available for download on Aeglea's website. Aeglea is focused on developing human enzyme therapeutics for rare diseases, notably its lead candidate pegzilarginase, currently in a Phase 3 trial for Arginase 1 Deficiency. The company has also received regulatory approval for another treatment, ACN00177, for Homocystinuria.
Positive
- None.
Negative
- None.
News Market Reaction – AGLE
On the day this news was published, AGLE gained 1.23%, reflecting a mild positive market reaction.
Data tracked by StockTitan Argus on the day of publication.
AUSTIN, Texas, June 01, 2020 (GLOBE NEWSWIRE) -- Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE), a clinical-stage biotechnology company developing a new generation of human enzyme therapeutics as innovative solutions for rare and other high-burden diseases, today announced it will provide a corporate overview at BIO Digital being held virtually June 8-12, 2020.
Presentation Details
Date: June 8-12, 2020
Presenter: Anthony G. Quinn, M.B. Ch.B., Ph.D., Aeglea’s president and chief executive officer
Location: https://www.bio.org/events/bio-digital
The presentation will be available for download on the Presentations & Events section of the Company’s website and also will be available on-demand to registered participants of BIO Digital at https://www.bio.org/events/bio-digital/sessions/620997.
About Aeglea BioTherapeutics
Aeglea BioTherapeutics is a clinical-stage biotechnology company redefining the potential of human enzyme therapeutics to benefit people with rare and other high burden diseases. Aeglea's lead product candidate, pegzilarginase, is in a pivotal Phase 3 trial for the treatment of Arginase 1 Deficiency and has received both Rare Pediatric Disease and Breakthrough Therapy Designations. The Company received approval of its Clinical Trial Application (CTA) for ACN00177 for the treatment of Homocystinuria by the United Kingdom’s Medicines and Healthcare Products Regulatory Agency (MHRA). Aeglea has an active discovery platform, with the most advanced program for Cystinuria. For more information, please visit http://aegleabio.com.
Media Contact:
Kelly Boothe, Ph.D.
Director, Corporate Communications
Aeglea BioTherapeutics
512.399.5458
media@aegleabio.com
Investor Contact:
Joey Perrone
Senior Director, Finance & Investor Relations
Aeglea BioTherapeutics
investors@aegleabio.com
FAQ
What will Aeglea BioTherapeutics present at BIO Digital 2020?
When is the BIO Digital event where AGLE will present?
How can I access Aeglea BioTherapeutics' presentation?
What are Aeglea's leading therapeutic candidates?
Has Aeglea received any designations for its therapies?
